Introduction
Hereditary Breast and Ovarian Cancer (HBOC) syndrome is primarily associated with germline mutations in the BRCA1 and BRCA2 genes. However, as genomic medicine evolves, it has become increasingly clear that mutations in other susceptibility genes also contribute significantly to cancer risk. While extensive research has characterized these mutations in Caucasian populations, there remains a critical data gap regarding the genetic landscape of HBOC in Chinese individuals. This study evaluates the prevalence and clinical predictors of deleterious mutations in a large cohort of 882 high-risk Chinese patients using a comprehensive 21-gene panel.
Addressing the Population Gap
Most clinical guidelines and risk assessment models for HBOC are derived from Western genomic databases. Because the mutation spectrum can vary significantly across different ethnic groups, applying these models to Asian populations without validation can lead to inaccuracies in risk assessment. Furthermore, traditional testing methods often focus on specific "hotspots," potentially overlooking novel or population-specific variants. This research addresses these gaps by utilizing Next-Generation Sequencing (NGS) to provide a broader view of the genetic architecture of HBOC in China.
Methodology
The study analyzed 882 high-risk Chinese individuals referred for genetic testing between January 2015 and March 2018. The cohort included patients with breast cancer (BC), ovarian cancer (OC), both (BC & OC), or a significant family history (FHx).
Testing was performed using the Oseq-BRCA panel, a 21-gene NGS assay developed by BGI Genomics. This panel targets core genes involved in the Fanconi anemia (FA) and Homologous Recombination (HR) pathways, including BRCA1, BRCA2, PALB2, CHEK2, ATM, and BRIP1. Variants were identified using a robust bioinformatics pipeline (including SOAPnuke, BWA, and GATK) and classified according to the American College of Medical Genetics and Genomics (ACMG) guidelines.
Key Findings
1. Overall Mutation Prevalence
Out of the 882 individuals tested, 172 (19.50%) were found to carry a total of 176 deleterious mutations. While BRCA1 (50.6%) and BRCA2 (27.8%) accounted for the majority of these findings, a significant 21.6% of mutations occurred in the other 14 susceptibility genes. This underscores the clinical necessity of moving beyond BRCA1/2-only testing to avoid missing over one-fifth of at-risk patients.
2. Subgroup Analysis and Clinical Predictors
The study revealed that the clinical presentation of the patient is a strong predictor of mutation likelihood:
- Breast and Ovarian Cancer (BC & OC): This subgroup exhibited the highest mutation frequency at 57.9%, suggesting that a dual diagnosis is a powerful indicator of a germline mutation.
- Ovarian Cancer only: 26.3% of these patients (115/429) carried a deleterious mutation. Within this group, mutations were significantly enriched in patients with a family history of breast or ovarian cancers (p < 0.05).
- Breast Cancer only: 11.88% of these patients (31/261) carried a deleterious mutation.
- Family History only: 11.0% of individuals with a strong family history but no personal diagnosis carried a mutation.
In the breast cancer subgroup, CHEK2 was the most frequently mutated non-BRCA gene. In contrast, BRIP1 and RAD51C were more prevalent among patients with ovarian cancer.
3. Genetic Novelty and the VUS Challenge
A major highlight of the study was the identification of 26 novel mutations not previously documented in public databases like ClinVar or LOVD. This finding emphasizes the importance of population-specific research; relying solely on Western-centric data may result in the misclassification or omission of relevant variants in Asian patients.
However, the study also highlighted the complexity of clinical genetics: 38.55% of the cohort carried a "Variant of Uncertain Significance" (VUS). The ATM gene had the highest number of VUS, likely due to its large transcript length. The high prevalence of VUS remains a significant challenge for clinicians, as the pathogenicity of these variants must be clarified before they can inform surgical or therapeutic decisions.
Discussion and Limitations
The results demonstrate that a 21-gene panel significantly increases the diagnostic yield for HBOC in the Chinese population compared to BRCA1/2 testing alone. The high mutation rate in the BC & OC subgroup supports the prioritization of these patients for comprehensive genetic screening.
Despite its strengths, the study has limitations. The sample sizes for certain subgroups (notably the BC & OC group with only 19 people) were relatively small, which may affect the statistical power of those specific findings. Additionally, because the cohort consisted of "high-risk" individuals referred for testing, the reported mutation frequencies are likely higher than those in the general population.
Conclusion
This research provides a vital baseline for the genetic landscape of HBOC in China. By identifying novel mutations and demonstrating the utility of multigene panels, the study advocates for a more nuanced, population-specific approach to cancer risk assessment. Future efforts should focus on functional assays to resolve VUS and longitudinal studies to determine how these genetic findings influence treatment responses, such as sensitivity to PARP inhibitors, in Chinese patients.
Summary updated